Get the Stockscreener App
0.772
5.98%
-0.0491
Pre-market:
.79
0.018
+2.33%
Genprex Inc stock is traded at $0.772, with a volume of 413.78K.
It is down -5.98% in the last 24 hours and down -24.31% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$0.8211
Open:
$0.7965
24h Volume:
413.78K
Relative Volume:
0.48
Market Cap:
$8.17M
Revenue:
-
Net Income/Loss:
$-16.23M
P/E Ratio:
-0.0519
EPS:
-14.8777
Net Cash Flow:
$-15.31M
1W Performance:
-2.03%
1M Performance:
-24.31%
6M Performance:
-73.38%
1Y Performance:
-94.39%
1-Day Range:
$0.7633
$0.8201
1-Week Range:
$0.7401
$0.8599
52-Week Range:
$0.7401
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.772 | 8.69M | 0 | -16.23M | -15.31M | -14.88 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex reports biomarker data from lung cancer gene therapy study - Investing.com UK
Genprex, Inc. Announces Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - marketscreener.com
Genprex reports biomarker data from lung cancer gene therapy study By Investing.com - Investing.com Nigeria
Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy - TipRanks
Biomarker data link Trop-2 to PFS in Genprex (NASDAQ: GNPX) trials - Stock Titan
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - PR Newswire
Genprex Inc. (GNPX) Edges Higher Amid Biotech Sector Cautious ToneLow Vol Factor - Newser
GNPX Should I Buy - Intellectia AI
Genprex (GNPX) Q1 2026 Earnings Stay the Course — EPS $-0.64Retail Trader Picks - Newser
Why Is Genprex, Inc. (GNPX) Stock Down Today? - Meyka
Genprex (GNPX) Showcases Promising Diabetes Gene Therapy Results - GuruFocus
Genprex, Inc. Files Form 8-K With SEC – Company Information and Filing Details for May 14, 2026 - Minichart
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT - TradingView
Genprex collaborators present diabetes gene therapy data - Investing.com
Genprex collaborators present diabetes gene therapy data By Investing.com - Investing.com UK
[8-K] Genprex, Inc. Reports Material Event - Stock Titan
Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Genprex (NASDAQ: GNPX) raises cash through share sales amid going concern risk - Stock Titan
Genprex (GNPX) warrant holders report 249,788 shares, 2.69% stake - Stock Titan
Number of shareholders of Genprex Inc – LSE:0A8I - TradingView
GNPX (Genprex) Q1 loss narrower than expected, beating estimates by 37.8% despite zero revenue and shares ticking higher.Miss Estimates - newser.com
Top 3 Health Care Stocks That Are Set To Fly In Q2 - Benzinga
GNPX Forecast, Price Target & Analyst Ratings | GENPREX INC (NASDAQ:GNPX) - ChartMill
MSN Money - MSN
Genprex, Inc. Files Form 8-K With SEC: Company Information, Nasdaq Listing, and Regulatory Details - Minichart
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatm - GuruFocus
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel - TipRanks
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - BioSpace
Genprex | 8-K: Current report - Moomoo
Israel grants Genprex (NASDAQ: GNPX) patent for REQORSA lung cancer use - Stock Titan
Genprex (NASDAQ: GNPX) seeks approval for equity plan and reverse stock split - Stock Titan
Genprex collaborators to present diabetes gene therapy data at May meeting By Investing.com - Investing.com Australia
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex collaborators to present diabetes gene therapy data at May meeting - Investing.com UK
average down - Moomoo
Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex (GNPX) shows GPX-002 gene therapy reversed hyperglycemia in T2D mice - Stock Titan
Genprex biomarker research selected for ASCO 2026 meeting By Investing.com - Investing.com India
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - StreetInsider
Genprex biomarker research selected for ASCO 2026 meeting - Investing.com
Lung cancer gene therapy study lands ASCO slot with biomarker data - Stock Titan
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - The Malaysian Reserve
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):